Meta-Analytic Contradictions
The primary tension in DHEA research lies in the divergence between oocyte quantity and live birth quality. Meta-analyses from 2023 and 2019 highlight a paradox: while DHEA significantly increases the number of retrieved oocytes (MD 0.88, 95% CI 0.54–1.23), this does not always translate to more babies. One review of 9 RCTs found a robust 76% increase in live birth rates, but a larger, more conservative pooling of only high-quality RCTs found the effect disappeared (Claim 4, 5).
This suggests a 'ceiling effect' or perhaps that DHEA only works for a very specific subset of women with profound androgen deficiency. For the broader population of women with diminished ovarian reserve, the benefit may be too marginal to overcome the statistical noise of standard IVF outcomes.
The Follicular Microenvironment
Mechanistically, DHEA acts as a precursor for follicular testosterone, which in turn upregulates Androgen Receptor (AR) expression in granulosa cells. This is thought to sensitize follicles to Follicle-Stimulating Hormone (FSH), potentially rescuing 'doomed' follicles from apoptosis. Preclinical models show DHEA may also attenuate the age-related decline of oocyte cohesin subunits, which are critical for preventing chromosomal misalignments (Claim 6).
However, clinical evidence remains mixed. A 2017 cohort study found that while 75mg of DHEA successfully increased serum testosterone and AR mRNA expression, it failed to improve actual IVF outcomes in that specific group compared to controls (Claim 7). This highlights a disconnect between biochemical priming and clinical success.
The Combinatorial Strategy
Newer research is shifting away from DHEA monotherapy toward combinatorial 'nutraceutical' priming. The addition of Coenzyme Q10 (CoQ10) to DHEA appears to address mitochondrial energetics that androgens alone cannot influence. Recent 2025 data shows that women receiving both experienced higher fertilization rates and more mature follicles (4.71 vs 3.70) than those on DHEA alone (Claim 8, 3).
- Standard protocol: 75 mg DHEA daily for 90 days prior to IVF.
- Synergistic adjuncts: CoQ10 600 mg daily.
- Primary monitoring: Baseline AMH and mid-priming Testosterone.